David J. Einstein
@davidjeinstein.bsky.social
Disease Group Leader, BIDMC GU Medical Oncology, Dana-Farber/Harvard Cancer Center
Now time for some caveats and context!
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/abs/10.1...
pubmed.ncbi.nlm.nih.gov/39985705/
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/abs/10.1...
pubmed.ncbi.nlm.nih.gov/39985705/
Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial
ascopubs.org
March 7, 2025 at 10:33 PM
Now time for some caveats and context!
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/abs/10.1...
pubmed.ncbi.nlm.nih.gov/39985705/
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/abs/10.1...
pubmed.ncbi.nlm.nih.gov/39985705/
6-7 pm EST: Advanced and Newly Diagnosed subgroups
7-8 pm EST: Ian Travis, PT DPT
@bidmcnews
discussing treatment of urinary incontinence
7-8 pm EST: Ian Travis, PT DPT
@bidmcnews
discussing treatment of urinary incontinence
February 3, 2025 at 4:30 PM
6-7 pm EST: Advanced and Newly Diagnosed subgroups
7-8 pm EST: Ian Travis, PT DPT
@bidmcnews
discussing treatment of urinary incontinence
7-8 pm EST: Ian Travis, PT DPT
@bidmcnews
discussing treatment of urinary incontinence
Increasingly I’m seeing it as an exclusion criterion in industry-led trials, esp ADCs. Makes no sense to single this out (unless there’s a taxane comparator arm). Use typical CBC cutoffs and make inclusion criteria as broad as possible.
December 16, 2024 at 1:15 PM
Increasingly I’m seeing it as an exclusion criterion in industry-led trials, esp ADCs. Makes no sense to single this out (unless there’s a taxane comparator arm). Use typical CBC cutoffs and make inclusion criteria as broad as possible.
